Zehui Bio's hESC-Derived Cell Therapy Receives IND Approval for Clinical Trials

2021Year9MonthOn the 26th, Zephyrm, a portfolio company of 3E BioventuresDevelopmentofM-021001 Cell Injection Received the "Drug Clinical Trial Approval" Issued by the National Medical Products Administration, Approving the Conduct of Clinical Trials.

Dr. Fang Yu, Partner at 3E Bioventures, stated, “In recent years, stem cell therapeutics have made significant strides across basic research, manufacturing processes, regulatory oversight, and clinical translation. Zephyrm has taken the lead in China by utilizing clinical-grade human embryonic stem cell lines, boasting advanced manufacturing technologies and ultra-high-standard facilities, with a commitment to advancing the industrialization of stem cell therapeutics. We firmly believe that stem cell therapeutics will bring revolutionary breakthroughs to the treatment of major diseases.”

This product is China’s first immune and stromal regulatory cell preparation derived from human embryonic stem cells.

Due to differences in cell sources and manufacturing processes, these cells exhibit significant advantages over adult mesenchymal stem cells (MSCs) in terms of functionality, purity, and homogeneity. They are also more conducive to scalable, standardized production, thereby addressing the global challenge of stable, large-scale cell manufacturing and advancing the industrialization of stem cell therapeutics.

In terms of cell origin, the development of stem cell drugs based on human embryonic stem cells has become a trend. The two Fast Track IND stem cell products approved by the FDA this year (DA01 for Parkinson’s disease, BlueRock; VX-880 for Type 1 diabetes, Vertex) are also derived from human embryonic stem cells.

In terms of manufacturing processes, cell therapy has emerged as a prominent new modality in drug development in recent years, with many companies exploring novel CAR-T, NK cell, and stem cell therapies. However, a critical bottleneck lies in establishing CMC (Chemistry, Manufacturing, and Controls) capabilities sufficient to support product commercialization—specifically, scalable manufacturing processes that ensure high purity and consistent quality.

Zephyrm has established a 2,400-square-meter GMP-compliant manufacturing facility in the Zhongguancun Science Park in Beijing. From design and construction to operation, the facility meets advanced international standards for the cell therapy industry, fully satisfying current demands for providing safe, reliable, and high-quality stem cell therapies to patients in China.

The official approval of the clinical trial registration marks the entry of the industrialization of a new generation of cell therapies, represented by cells differentiated from human embryonic stem cells, into a period of rapid development.

Another significant advantage of M-021001 cells derived from human embryonic stem cells as a therapeutic agent is that only a single process validation is required, allowing the same cell product to be explored for different indications.

The clinical trial approved this time targets the indication of meniscal injury. Meniscal injury is an osteoarticular disease caused by damage to the cartilage tissue within the knee joint, resulting from degeneration, sports activities, or other external forces. Due to factors such as insufficient blood supply, the meniscus has poor self-repair capabilities. Currently, there is a lack of specific therapeutic methods or drugs in clinical practice.

In addition to meniscal injury repair, M-021001 cells also hold the potential for further expansion of indications.

During the COVID-19 pandemic in 2020, this product received approval from the National Medical Products Administration (NMPA) for Phase I/II clinical trials of a new drug, intended for the treatment of respiratory distress syndrome and pulmonary fibrosis caused by severe COVID-19.

Furthermore, this product holds promise for continued expansion into various indications, including premature ovarian insufficiency, graft-versus-host disease (GVHD), osteoarthritis, and diabetic foot.

Zephyrm is a clinical-stage biopharmaceutical company primarily engaged in the research and development of stem cell-based therapeutics and cell preparation. It is the only enterprise in China that has successfully developed approved drugs derived from human embryonic stem cells. Upholding rigorous scientific standards and a spirit of exceptional innovation, Zephyrm develops stem cell therapies with independent intellectual property rights in China, aiming to address unmet medical needs that cannot be adequately managed by conventional drugs and treatments—such as neurodegenerative diseases, metabolic disorders, and reproductive function decline—thereby advancing the clinical application and industrial translation of stem cell technologies.

3E Bioventures is a specialized investment fund dedicated to investing in globally leading life sciences and healthcare companies, with a focus on two key areas: innovative pharmaceuticals and cross-disciplinary innovative medical devices and diagnostic technologies. The core founding team members all hold PhDs in biomedical-related fields from overseas institutions, bringing years of practical experience in the pharmaceutical and biotechnology industries, as well as over a decade of successful investment and entrepreneurial experience both domestically and internationally. They combine professional expertise, industry insight, and a global perspective.

3E Bioventures is a dual-currency fund manager operating in both RMB and USD. It has cumulatively invested in and incubated over 70 domestic and international healthcare innovation enterprises, with offices in Beijing, Shanghai, and Silicon Valley. Upholding the vision of “building great healthcare companies and establishing an internationally recognized professional investment brand,” 3E Bioventures empowers outstanding entrepreneurial teams and delivers superior returns to its investors.